. We explored the association between these publications and national trends in CAS use among high-risk symptomatic patients.
high-quality studies comparing these modalities in the intervening years, there remains a question of equipoise between them. The use of CAS steadily increased after its approval by the United States Food and Drug Administration (FDA) in March of 2004 and subsequent approval by the Centers for Medicare and Medicaid Services (CMS) in 2005. 3, 4 In 2008, after a few publications suggested higher morbidity and mortality with CAS, CMS approved conditional payment of CAS in high-risk patients with symptomatic carotid stenosis, publishing guidelines (CMSG) for its use [5] [6] [7] and defining high-risk as patients having significant comorbidities, such as congestive heart failure (CHF), unstable angina, or recent myocardial infarction, or anatomic risk factors, such as prior neck dissection or neck irradiation. 7 Publication of the CMSG did not lead to cessation of CAS use, and CAS continued to be performed outside of the CMSG 5, 6 and by different specialties, although perhaps at a slightly lower rate. 3, 8 The Carotid Revascularization Endarterectomy versus Stent Trial (CREST) trial, a prospective randomized trial published in 2010, suggested that CAS and CEA patients had similar composite adverse outcomes, with CAS patients having higher rates of postoperative stroke. 9 Since 2010, the debate over CAS or CEA has continued, with many citing the increased stroke rate as a reason to temper enthusiasm for CAS. 10, 11 We previously used a national database to analyze trends in CAS use in relation to the publication of the CMSG in 2008 and CREST in 2010, showing a small but statistically significant decrease in CAS use after CMSG, followed by a steady but not significant increase in the rate of CAS after the publication of CREST. 3 In this study, we sought to further evaluate trends of CAS use in a high-risk subset of patients, again using a national database to determine whether the publication of the CMSG and CREST affected rates of CAS. Because CMSG specifically suggested a high-risk subset of symptomatic patients be considered for CAS, we hypothesized that rates of CAS would increase in these patients. We also sought to see whether the suggestion in CREST that CAS led to higher stroke rates would lead to changes in CAS use in high-risk symptomatic patients.
METHODS
As described previously, the Nationwide Inpatient Sample (NIS) was used to evaluate the national trends across multiple specialties performing CAS across the United States. 3, 5, 6 The Boston University School of Medicine Institutional Review Board approved the use of deidentified data for the initial study and this subsequent analysis, and because this is a deidentified database, individual patient consent was not required. Further information about this database can be found online. 12 The NIS was queried for calendar years 2005 to 2011 for patient discharges after carotid revascularization. Significant changes made to the NIS database structure after 2011 make comparison of newer data to that from prior years both difficult and likely inaccurate. The details of NIS can be found at its Web site, and the methodology is similar to previously published studies. 5, 13 As previously described, all patients undergoing carotid revascularization for carotid artery stenosis were identified using International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM codes) 14 for CAS (ICD-9-CM procedure code 00.63) or CEA (38.12) and further subdivided based on the absence (433.10) or presence of neurologic symptoms (433.11). 5, 13 Patients with combined CAS and CEA codes were excluded from this study to allow for homogeneity of the cohorts and better comparison between the two groups. Patients with postoperative stroke were identified using ICD-9-CM code 997.02. Patient comorbidities were also collected and components of the Charlson Comorbidity Index (CCI) 14 were used to determine the "high-risk" cohort (CCI $3). These included CHF (1 point), peripheral vascular disease (PVD; 1 point), chronic obstructive pulmonary disease (1 point), diabetes mellitus (2 points), renal failure (2 points), peptic ulcer disease (1 point), and liver disease (1 point).
Statistical analyses. Statistical analysis was performed as previously described. 3, 4 Briefly, the outcomes of interest were identified from the NIS sample and included in-hospital mortality (IHM) and in-hospital postprocedure stroke during the index admission. Elixhauser comorbidity SAS macro sets (SAS Institute Inc, Cary, NC), which are designed for use with administrative data sets such as NIS, 15 were used to identify patient comorbidities. We used c 2 tests in bivariate comparisons of categoric variables among the procedures and used t-tests to compare continuous variables. We performed multivariable logistic regression to determine whether the type of procedure was associated with higher odds of postoperative stroke or IHM. Covariates included patient age, gender, insurance type, and comorbid conditions (hypertension, diabetes mellitus, chronic lung disease, coronary artery disease CHF, and renal failure).
The NIS sample was divided into three time intervals to perform trend analyses. To improve the fidelity of trend analyses each year was also divided into four quarters (Q1-Q4). These time intervals were selected in relation to the publication of the CMSG in 2008 previously, the NIS beyond 2011 shows significant changes that would make the comparison of data with the prior years impossible). To estimate different trends in use of CAS in high-risk patients, we performed logistic regression analyses with piecewise linear trends for time within each interval. 13, 16 Similar to the analysis with the overall cohort published previously, we also analyzed trends of use in all high-risk patients as well as in high-risk patients with preoperative neurologic symptoms. Multivariable logistic regression was again used to determine whether changes in use affected adverse outcomes. SAS 9.3 software was used for all statistical analyses, and for all tests, a P value of <.05 was considered statistically significant.
RESULTS
We identified 172,719 eligible carotid revascularization procedures in the NIS database during the specified time period. Of these, 23,526 patients were determined to be high-risk (CCI $3). Basic demographic characteristics of the high-risk patients are summarized in Table I . CAS accounted for 14.7% (n ¼ 3447) of carotid revascularization procedures in high-risk patients. Overall the vast majority of cases, both for CAS and CEA, were performed in asymptomatic patients (>90% for both groups). Nonelective admissions were significantly more likely in the CAS group than in the CEA group, and CAS patients were significantly more likely to be symptomatic, although overall 95.2% of patients in both groups were asymptomatic. Components of the high-risk determination were variable, because high-risk patients undergoing CAS had significantly higher rates of CHF, PVD, or renal failure, whereas those undergoing CEA were more likely to have chronic obstructive pulmonary disease, diabetes, or liver failure. Table II summarizes the characteristics of patients who were high risk and symptomatic. The symptomatic high-risk patients undergoing CAS or CEA were relatively comparable in characteristics, with only higher rates of CHF among CAS patients and CEA patients having a higher obesity rates (Table II) .
Comparison of outcomes. Rates of postoperative stroke and IHM were compared between high-risk patients undergoing CAS and CEA (Fig 1) . The IHM rate in this high-risk cohort was 0.4% overall, comparable to the 0.3% rate previously reported in all NIS patients from this time period.
3 IHM rates were not significantly different between CAS and CEA patients overall (0.6% vs 0.4%; P ¼ .296), but were significantly higher among symptomatic patients undergoing CAS (4.7% vs CEA 2.0%; P ¼ .021, Fig 1, A) . The overall postoperative in-hospital stroke rate in this high-risk cohort was 0.9%, also comparable to the 1% stroke rate previously reported (Fig 1, B) .
3 CAS in highrisk patients was associated with significantly higher rates of stroke overall (1.4% vs CEA 0.9%; P ¼ .004) but stroke rates, although higher among CAS cases, were not significantly different in symptomatic high-risk patients (CAS 3% vs CEA 2.1%; P ¼ .433). Multivariable logistic regression analyses showed no significant difference in odds ratios (ORs) of IHM in high-risk patients undergoing CAS or CEA; however, the OR for IHM compared with CEA was significantly higher in symptomatic high-risk patients treated with CAS (OR, 2.56; 95% confidence interval [CI], 1.17-5.62; P ¼ .019; Fig 2) . The odds of postoperative in-hospital stroke were also significantly higher among high-risk CAS patients overall (OR, 1.39; 95% CI, 1.03-1.89; P ¼ .033) but were not different in symptomatic patients (Fig 2) . We have previously described the overall outcomes in different periods. The results for high-risk patients in different time periods are summarized in the Supplementary Table (online only) .
Trends in use and outcomes of CAS in high-risk patients in the three time periods. Table III , A and B, summarize the trend analysis of each period and comparisons between two periods in highrisk patients. Overall, the odds of CAS use (vs CEA) for carotid revascularization in high-risk patients increased significantly during P1 before the publication of the CMSG (trend 2005-2008; OR 1.02; 95% CI, 1.01-1.04; P < .001). The odds of CAS use in high-risk patients did not significantly change in P2, the period between the publication of the CMSG and the CREST trial (OR, 0.99; 95% CI, 0.97-1.01; P ¼ .31). However, the odds of CAS being used were significantly less in P2 compared with P1 (OR, 0.967; 95% CI, 0.94-0.99; P ¼ .01). P3, after the publication of CREST, saw a significant increase in the odds of CAS use among high-risk patients (OR, 1.05; 95% CI, 1.02-1.08; P ¼ .002), and the odds of CAS use in high-risk patients were significantly higher in P3 compared with P2 (OR, 1.06; 95% CI, 1.01-1.10; P ¼ .012). CAS use did not differ significantly in symptomatic high-risk patients in any time period, meaning that increases in CAS use were driven by increases in asymptomatic high-risk patients (Table III, B) .
DISCUSSION
The publication of the CMSG in 2008 laid out a framework for the reimbursement of CAS in general and in high-risk patients in particular by limiting reimbursement of CAS to high-risk, symptomatic patients. The CREST publication provided Level I evidence comparing the outcomes after CAS and CEA. 9 Our study examined the association of those two seminal publications on the use of CAS in high-risk patients in the NIS data set. We found that, similar to the previous report of Eslami et al 3 in all patients in the NIS database, the overall use of CAS in high-risk patients increased throughout the study period. There was no significant change in CAS use in high-risk, symptomatic patients throughout the study period, implying that changes in CAS use were driven by its use in asymptomatic high-risk patients. Similar to the overall cohort, 3 CAS use increased in high-risk patients before the CMSG publication. Somewhat surprisingly, no change occurred in the use of CAS in all high-risk patients after CMSG. A similar observation was made among the symptomatic high-risk patients between the publication of CMSG and CREST, despite CMSG specifically allowing for CAS reimbursement among the high-risk symptomatic patients. The period after the publication of CREST, which suggested equipoise between CAS and CEA, saw a significant increase in the use of CAS in high-risk patients, again driven by its use in asymptomatic patients. These trends in high-risk patients occurred despite significantly higher odds of IHM in symptomatic high-risk patients undergoing CAS and significantly higher odds of stroke in all high-risk patients undergoing CAS. Although a delay often occurs between the publication of guidelines or trials and changes in clinical practice, there appear to be clear changes in CAS use related to both the CMSG and CREST publications. Early proponents of CAS suggested that it may be beneficial in high-risk surgical patients because CAS avoids general anesthesia and the stress response associated with open surgery. The increased use of CAS has been well documented in prior studies. 3, 4, 8 CAS has been found to be increasingly used despite a decrease in the overall number of carotid revascularization procedures. 17, 18 This has occurred despite both higher charges incurred by CAS and worse outcomes in perioperative mortality and stroke. 4 As previously posited, this decrease in carotid procedures may be secondary to the publication of several studies questioning its utility in asymptomatic patients. 3, 19, 20 Our results indicate that the national use of CAS in high-risk asymptomatic patients has increased throughout this study period. As described, the CMSG publication allowed for conditional payment for CAS in high-risk, symptomatic patients. These guidelines led to a significant decrease in the use of CAS in all patients, 3 whereas the use in high-risk patients did not significantly change, as observed here. Because w80% of the patients in the NIS sample were Medicare or Medicaid recipients (Table I) , it is surprising that the use of CAS in this highrisk population did not increase significantly. Before the publication of the CREST trial, many observational studies and large, randomized multi-institutional trials were published suggesting that CAS is associated with higher in-hospital stroke and mortality rates. [4] [5] [6] 21, 22 The CREST results 9 led the American Heart Association to suggest that CEA and CAS are comparable 23 and that prophylactic CAS should be performed in asymptomatic patients. 24 This suggestion of equipoise between the procedures has since been the subject of much debate, and Paraskevas et al 25 have observed that although the main purpose of CAS and CEA is stroke prevention, the choice of myocardial infarction as part of the composite adverse events end point was the main driver for the suggested procedural equivalence in CREST. This study suggests that despite this ongoing debate, the use of CAS in high-risk patients increased significantly after CREST, driven by an increase in its use in asymptomatic patients. Although a causal link is difficult to prove, it has been suggested that the enthusiastic response of the American Heart Association likely has played a large role in this increase, especially because most CAS procedures are performed not by vascular surgeons but by interventional cardiologists and other specialists. 3, 9, 26 The analyses of large administrative datasets, such as the NIS, have several limitations, including their inherent retrospective nature and inability to account for postprocedural events beyond the index admission. 27 In addition, although the NIS is a large, nationally representative database, it lacks some clinically relevant details and may incorporate coding errors regarding patient comorbidities and complications. One major detail not included is anatomic high-risk considerations, meaning that the high-risk cohort used in this study does not align perfectly with the CMS high-risk stratification. Prior studies have also suggested that the NIS database is poorly equipped to accurately determine between preoperative or postoperative neurologic symptoms. 28 One important issue that may contribute to this is the lack of ICD-9-CM codes for transient ischemic attack. ICD-9-CM codes only include patients with carotid stenosis with (433.11) or without (433.10) cerebral stroke. There are no secondary codes to define patients with carotid stenosis and transit ischemic attack only.
Despite this, we feel that this database can viably be used to compare CAS and CEA in high-risk patients. As discussed in the prior study looking at the overall cohort, although it is possible that some errors may have been made in entering/coding comorbidities and complications, there likely was no bias in coding errors between one procedure and the other. In addition, coding of procedure types is generally correct, allowing accurate analyses of utilization trends. One last limitation is that the data used include only results until 2011. This is due to significant changes in the NIS database structure, which makes the comparison difficult with prior years. The study, therefore, does not have the additional years of data since CREST. We are in the process of accruing other databases to study the effects of CAS use in the more recent period after CREST.
Even with these limitations, we show that the use of CAS in high-risk patients increased throughout the study period despite CAS leading to increased rates of stroke overall and increased IHM in symptomatic patients. In addition, CAS continues to be performed on a large number of asymptomatic high-risk patients, despite lack of clear evidence of its utility in this group.
CONCLUSIONS
Further analysis of a large, national, population-based database demonstrates that the use of CAS for carotid revascularization in a high-risk cohort of patients significantly increased from 2005 to 2011. Similar to the overall cohort and other previous studies, compared to CEA, CAS independently increased the odds of perioperative in-hospital stroke in all high-risk patients and of IHM in symptomatic high-risk patients. Further studies, including the currently enrolling CREST II trial, are needed to clearly define the role of CAS overall as well as in high-risk patients.
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